The first human ledger
Phase 2 diabetes · Published December 14, 2023
Can glucose and weight improve without ignoring tolerability?
Subject One opens a ledger with two columns: findings and difficulties. He tries to make the second column narrower. Doctide turns the book sideways. “Both have to fit.” The visitor copies the headings at equal size.
What changes here
A short diabetes trial found improvements, but treatment-related serious harms also occurred. [1]
Read the study details & dates
Adults with type 2 diabetes
413 adults (18–75 years, BMI 25–50) on metformin were randomized to six subcutaneous survodutide regimens, placebo, or open-label semaglutide 1 mg. HbA1c was the primary endpoint. Mixed-model repeated-measures estimates showed reductions up to 1.71 percentage points; weight fell up to 8.7%, versus 5.3% with semaglutide. These maxima came from different survodutide groups. [1] [2]
What this does not establish
The semaglutide reference arm was open-label. Sixteen weeks cannot establish long-term outcomes or superiority to other formulations. The reviewed main text does not provide a comprehensive mortality breakdown.
Original sources
Primary full text and Table 3 reviewed through Europe PMC XML on October 27, 2026. Investigator-classified drug-related events are reported without inventing individual patient outcomes.
Subject One is fictional. Separate studies, species and populations are not a single patient’s experience. How to read the story